Phase II Study on AK104 in Neoadjuvant Treatment of Cervical Cancer
Latest Information Update: 05 Nov 2024
At a glance
- Drugs Cadonilimab (Primary)
- Indications Carcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Akeso Biopharma
- 01 Nov 2024 Status changed from not yet recruiting to completed.
- 10 Feb 2022 New trial record